Intelligent Bio Solutions Inc.
INBSIntelligent Bio Solutions Inc. in brief
Intelligent Bio Solutions Inc. is a listed company in the Healthcare sector, based in New York, New York, USA. Its market value was $6 M on 22 October 2026, which makes it the 26,767th largest listed company in the world and the 4,386th largest in the USA on this site. In the year to June 2026 it had sales of $4 M and a net loss of $12 M. It employs about 13 people and Harry Simeonidis is its chief executive. Its largest product and service lines by sales in 2026 were Sales of Goods - Cartidges (59%) and Sales of Goods - Readers (21%). By market, the largest shares of its 2026 sales came from UK (99%), Asia Pacific (under 1%) and Americas (under 1%). Its shares trade under the symbol INBS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December 5, 2016, under the laws of the state of Delaware. The Company’s Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales, Australia. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited, a company registered in England and Wales. Our headquarters are in New York City.
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. The Company operates globally with the objective of providing innovative and accessible solutions that improve the quality of life.
From the company's annual report filed with the US SEC: read the report
Intelligent Bio Solutions Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- ✎Renamed GBS Inc.Formerly Glucose Biosensor Systems (Greater China) Holdings, Inc..
- 2020
- 🔔Initial public offering as GBS Inc.Final prospectus filed with the SEC on 28 December 2020; shares registered for exchange trading on 22 December 2020.
- 2022
- ✎Renamed Intelligent Bio Solutions Inc.Formerly GBS Inc..
- 2026
- 💰Record revenue of $4 millionFY2026, the highest of the 7 years on record.
Events of Intelligent Bio Solutions Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,759 (Dec 2022) · #5,619 (Jul 2023) · #4,685 (Jan 2024) · #2,417 (Mar 2026) · #4,085 (Aug 2026) · #4,360 (Oct 2026) · #4,388 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.3×
- Price / book
- 1.0×
- Free cash flow yield
- -210.1%
- Net margin (TTM)
- -269.1%
- Operating margin
- -298.8%
- Return on equity
- -219.8%
- Liabilities / assets
- 55.7%
- Revenue growth
- +38.4%
- Revenue per employee
- $325 K
- Profit per employee
- $-956 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $4M | +38.4% | $-13M | $-12M | -294.5% |
| Jun 2025 | $3M | -1.9% | $-11M | $-11M | -346.6% |
| Jun 2024 | $3M | +146.8% | $-10M | $-10M | -326.7% |
| Jun 2023 | $1M | +186.4% | $-13M | $-11M | -843.7% |
| Jun 2022 | $0M | -77.8% | $-8M | $-8M | -1888.6% |
| Jun 2021 | $2M | +942.1% | $-6M | $-7M | -355.6% |
| Jun 2020 | $0M | — | $-3M | $-3M | -1663.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $-12M | $0M | $-12M | $-8.44 | — |
| Jun 2025 | $-10M | $0M | $-10M | $-20.04 | — |
| Jun 2024 | $-10M | $0M | $-10M | $-6.38 | — |
| Jun 2023 | $-7M | — | — | $-127.00 | — |
| Jun 2022 | $-3M | — | — | $-11.33 | — |
| Jun 2021 | $-11M | — | — | $-0.68 | — |
| Jun 2020 | $-1M | — | — | $-0.37 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+25.2% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 2, 2026DEF 14AProxy statement
- Oct 21, 202610-K/AAnnual report (amended) · period to Jun 2026
- Oct 13, 20268-KCurrent reportBylaws amended · Regulation FD disclosure
- Sep 11, 20268-KCurrent reportOther events
- Sep 9, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 2, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Sep 1, 20268-KCurrent reportRegulation FD disclosure
- Aug 28, 20268-KCurrent reportRegulation FD disclosure
- Aug 19, 20268-KCurrent reportResults of operations
- Aug 19, 202610-KAnnual report · period to Jun 2026
Official filings of Intelligent Bio Solutions Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $4 M
- Operating income
- $-13 M
- Net income
- $-12 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $12 M
- Total liabilities
- $7 M
- Total equity
- $6 M
As of June-2026
Top 9 institutional investors in Intelligent Bio Solutions Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.P. | 70,034 | New | 2.11% | $0 M | Nov 16, 2026 |
| 2 | Geode Capital Management, LLC | 17,882 | -2,958 (-14.19%) | 0.54% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Capital Management LLC | 12,603 | +6,793 (+116.92%) | 0.38% | $0 M | Nov 13, 2026 |
| 4 | StoneX Group Inc. | 11,217 | New | 0.34% | $0 M | Nov 3, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 3,958 | 0 (0.00%) | 0.12% | $0 M | Nov 13, 2026 |
| 6 | UBS Group AG | 1,363 | -4,372 (-76.23%) | 0.04% | $0 M | Nov 10, 2026 |
| 7 | Tower Research Capital LLC (TRC) | 1,355 | -1,925 (-58.69%) | 0.04% | $0 M | Nov 16, 2026 |
| 8 | Osaic Holdings, Inc. | 200 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 9 | Jpmorgan Chase & Co | 13 | New | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Intelligent Bio Solutions Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 12,545 | $0 M | 0.38% | <0.01% | +70% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 5,810 | $0 M | 0.18% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,769 | $0 M | 0.05% | <0.01% | +25% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 409 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Intelligent Bio Solutions Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Spiro Kevin SakirisChief Financial Officer | Grant or award | +9,150 | — | — | 12,631 | Form 4 |
| filed | Steven Constantine BoyagesDirector | Grant or award | +5,000 | — | — | 5,031 | Form 4 |
| filed | Jason IsenbergDirector | Grant or award | +5,000 | — | — | 5,000 | Form 4 |
| filed | Harry SimeonidisChief Executive Officer | Grant or award | +9,150 | — | — | 13,190 | Form 4 |
| filed | Nicola Marion FraserDirector | Grant or award | +5,000 | — | — | 5,000 | Form 4 |
| filed | Jonathan Scott HurdDirector | Grant or award | +5,000 | — | — | 5,006 | Form 4 |
| filed | Spiro Kevin SakirisChief Financial Officer | Grant or award | +21,350 | — | — | 33,981 | Form 4 |
| filed | Harry SimeonidisChief Executive Officer | Grant or award | +21,350 | — | — | 34,540 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Intelligent Bio Solutions Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-01-05 14:30 UTC, code LUDP, resumed 14:35 UTC
- 2025-12-31 15:07 UTC, code LUDP, resumed 15:12 UTC
- 2025-12-31 14:51 UTC, code LUDP, resumed 14:56 UTC
- 2025-12-31 14:31 UTC, code LUDP, resumed 14:41 UTC
- 2025-12-16 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 267 shares at $1.73
- : 413 shares at $1.53
- : 622 shares at $1.50
- : 2,042 shares at $1.45
- : 1,807 shares at $1.48
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Intelligent Bio Solutions Inc. scorecard#
Passes 7 of the 19 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (1 of 5). Fiscal year 2026; market cap of Oct 22, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.0×Price to book 1.0× against Healthcare's median of 3.1×.
- ✓Price to sales below its peers' median1.3×Price to sales 1.3× against Healthcare's median of 3.8×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 6
- ✓Revenue grew in the newest year38.4%Revenue up 38.4% in fiscal 2026.
- ✓Revenue up more than 5% a year over three years49.6%49.6% a year over the three years to fiscal 2026.
- ✓Faster growth over three years than its peers' median49.6%49.6% a year against Healthcare's median of 8.5% (549 companies).
- ✗Earnings per share grew in the newest year-8.44 vs -20.04Diluted EPS -8.44 in fiscal 2026 against -20.04 the year before (report's currency).
- ✗Net income higher than five years earlier-$12 M-$12 M in fiscal 2026 against -$7 M in 2021.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2026.
Profitability1 of 5
- ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- ✗Operating margin above its peers' median-298.8%-298.8% against Healthcare's median of -7.7% (674 companies).
- ✗Return on equity above 15%-292.1%-292.1% in fiscal 2026.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-298.8%-298.8% in fiscal 2026 against -1000.0% in 2023.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.44 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- ✗Altman Z-score outside the distress zone-11.19Z-score -11.19 (distress zone) for fiscal 2026.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year179.5%Diluted shares up 179.5% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2026#
Worked out from Intelligent Bio Solutions Inc.'s statements, beside the median of Healthcare.
| Ratio | Trend | 2026 | Median of peers |
|---|---|---|---|
| Operating margin | -298.8% | -7.7% | |
| Net margin | -294.6% | -8.1% | |
| Return on equity | -292.1% | -36.9% | |
| Revenue growth, 3 years a year | 49.6% | 8.5% | |
| Revenue growth | 38.4% | 10.2% | |
| Free cash flow margin | -285.8% | -1.3% |
4of 8on the Piotroski tests of financial strength
- Net loss of $12 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$12 million.
- The share count rose 179.5% in the year.
Intelligent Bio Solutions Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 4,215+38.1%100% | 3,053−1.9%100% | 3,112+148%100% | 1,257+188%100% | 437−77.9%100% | 1,980+949%100% | 189—100% | |
| Cost of revenue | 2,165+19.9%51.4% | 1,806+7.1%59.2% | 1,686+81.3%54.2% | 930—74.0% | — | — | — | |
| Gross profit | 2,050+64.4%48.6% | 1,247−12.5%40.8% | 1,426+336%45.8% | 327—26.0% | — | — | — | |
| Selling, general and administrative | 10,502+17.8%249% | 8,918—292% | — | — | — | — | — | |
| General and administrative | 10,502+17.8%249% | 8,918r8,884−3.7%292% | 9,258+15.3%298% | 8,027+63.1%639% | 4,920+46.5%1126% | 3,359+52.5%170% | 2,203—1167% | |
| Operating expenses | 15,336+20.3%364% | 12,743r12,708+5.0%417% | 12,134−11.2%390% | 13,660+55.7%1087% | 8,774+16.2%2007% | 7,554+148%381% | 3,046—1614% | |
| Operating income | −12,608—−299% | −10,679r−10,645—−350% | −10,283—−330% | −12,595—−1002% | −8,337—−1907% | −5,573—−281% | −2,857—−1514% | |
| Interest and finance income | 110+8.7%2.6% | 102+19.7%3.3% | 85—2.7% | — | — | — | — | |
| Interest expense and finance costs | 11−59.2%0.3% | 26r61−84.2%0.9% | 167—5.4% | — | — | — | — | |
| Share of profit of associates | — | — | — | — | — | −136−212%−6.9% | 122—64.5% | |
| Other non-operating income (expense) | 139+87.7%3.3% | 74r40−19.5%2.4% | 92−95.2%3.0% | 1,931+66475%154% | 2.9—0.7% | −1,487—−75.1% | −336—−178% | |
| Income before tax | — | — | — | — | — | −7,060—−356% | −3,193—−1692% | |
| Net income including minority interests | −12,469—−296% | −10,605—−347% | −10,191—−327% | −10,665—−848% | −8,334—−1906% | −7,060—−356% | −3,193—−1692% | |
| Minority interests' share of net income | −38—−0.9% | −36—−1.2% | −34—−1.1% | −33—−2.6% | −28—−6.4% | −23—−1.2% | −29—−15.5% | |
| Net income attributable to shareholders | −12,431—−295% | −10,569—−346% | −10,157—−326% | −10,632—−846% | −8,306—−1900% | −7,037—−355% | −3,164—−1676% | |
| Earnings per share, basic | -8.44—— | -20.04r-2.00—— | -6.38—— | -127.00r-10.58—— | -11.33r-0.57—— | -0.68—— | -0.37—— | |
| Earnings per share, diluted | -8.44—— | -20.04r-2.00—— | -6.38—— | -127.00r-10.58—— | -11.33—— | -0.68—— | -0.37—— | |
| Shares, weighted average (basic) | 1.5+179%— | 0.5r5.3−66.9%— | 1.6+1803%— | 0.1r1.0−88.6%— | 0.7r15−93.0%— | 10—— | — | |
| Shares, weighted average (diluted) | 1.5+179%— | 0.5r5.3−66.9%— | 1.6+1803%— | 0.1r1.0−88.6%— | 0.7−93.0%— | 10+22.4%— | 8.5—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 3,992+291%33.4% | 1,020−83.8%12.4% | 6,304+310%45.8% | 1,537−81.3%14.8% | 8,238−34.5%66.7% | 12,574+2843%57.5% | 427—17.3% | |
| Receivables | 848+42.7%7.1% | 595+38.4%7.2% | 430+46.2%3.1% | 294—2.8% | — | — | — | |
| Inventory | 419−34.1%3.5% | 635−18.3%7.7% | 778−20.7%5.6% | 980—9.5% | — | — | — | |
| Other current assets | 1,031+24.7%8.6% | 827+66.2%10.0% | 498−10.0%3.6% | 553−26.0%5.3% | 747−70.2%6.0% | 2,509+5014%11.5% | 49—2.0% | |
| Current assets | 7,097+71.5%59.4% | 4,139−51.5%50.2% | 8,534+121%61.9% | 3,863−64.5%37.3% | 10,868−40.3%88.0% | 18,207+678%83.3% | 2,340—94.5% | |
| Property, plant and equipment | 294+17.1%2.5% | 251−55.6%3.0% | 566−18.0%4.1% | 690+76.3%6.7% | 391—3.2% | — | — | |
| Right-of-use (leased) assets | 1,751+2419%14.7% | 70−77.3%0.8% | 307−43.9%2.2% | 546—5.3% | — | — | — | |
| Other intangible assets | 2,799−26.1%23.4% | 3,790−13.3%45.9% | 4,372−16.8%31.7% | 5,255—50.8% | — | — | — | |
| Total assets | 11,942+44.8%100% | 8,250−40.1%100% | 13,779+33.1%100% | 10,355−16.2%100% | 12,352−43.5%100% | 21,859+783%100% | 2,476—100% | |
| Accounts payable | 712−20.6%6.0% | 897r4,534−47.4%10.9% | 1,705−34.7%12.4% | 2,610+60.6%25.2% | 1,625+10.7%13.2% | 1,468r1,570+86.4%6.7% | 787—31.8% | |
| Current liabilities | 4,929−7.9%41.3% | 5,351−1.8%64.9% | 5,451−7.4%39.6% | 5,884+26.2%56.8% | 4,663+26.6%37.8% | 3,683−52.1%16.8% | 7,690—311% | |
| Lease liabilities (non-current) | 1,672—14.0% | — | 81−77.2%0.6% | 356—3.4% | — | — | — | |
| Total liabilities | 6,651+22.4%55.7% | 5,436−2.9%65.9% | 5,596−16.1%40.6% | 6,668+14.8%64.4% | 5,806−15.3%47.0% | 6,853−10.9%31.3% | 7,690—311% | |
| Retained earnings | −74,964—−628% | −62,533—−758% | −51,964—−377% | −41,808—−404% | −31,176—−252% | −22,870—−105% | −15,833—−640% | |
| Shareholders' equity | 5,511+83.9%46.1% | 2,996−64.0%36.3% | 8,329+119%60.5% | 3,799−42.7%36.7% | 6,625−56.0%53.6% | 15,058—68.9% | −5,187—−210% | |
| Minority interests | −220—−1.8% | −182—−2.2% | −146—−1.1% | −112—−1.1% | −79—−0.6% | −51—−0.2% | −28—−1.1% | |
| Total equity | 5,291+88.0%44.3% | 2,814−65.6%34.1% | 8,183+122%59.4% | 3,687−43.7%35.6% | 6,546−56.4%53.0% | 15,007r15,007—68.7% | −5,215—−211% | |
| Total liabilities and equity | 11,942+44.8%100% | 8,250−40.1%100% | 13,779+33.1%100% | 10,355−16.2%100% | 12,352−43.5%100% | 21,859+783%100% | 2,476—100% | |
| Shares outstanding | 2.9+297%— | 0.7r7.3−78.8%— | 3.5+1680%— | 0.2r2.3−73.9%— | 0.7r15−94.5%— | 14+57.4%— | 8.6—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 1,164+20.0%27.6% | 970−0.4%31.8% | 974+19.6%31.3% | 814—64.8% | — | — | — | |
| Share-based compensation | 195−18.0%4.6% | 238+3.3%7.8% | 230−11.3%7.4% | 260—20.7% | — | — | — | |
| Cash from operating activities | −11,927—−283% | −9,677—−317% | −9,572—−308% | −7,377—−587% | −3,358—−768% | −11,296—−570% | −499—−264% | |
| Capital expenditure | −126—−3.0% | −232—−7.6% | −221r−5.4—−7.1% | — | — | — | — | |
| Acquisitions, net of cash acquired | — | — | — | −364—−28.9% | — | — | — | |
| Cash from investing activities | −86—−2.0% | −232—−7.6% | −221—−7.1% | −694—−55.2% | −880—−201% | — | −14—−7.4% | |
| Shares issued | — | — | — | — | — | 508—25.7% | — | |
| Cash from financing activities | 14,984+226%355% | 4,598−68.4%151% | 14,561+914%468% | 1,435—114% | — | 23,403+3089%1182% | 734—389% | |
| Change in cash | 2,972—70.5% | −5,284−211%−173% | 4,767—153% | −6,701—−533% | −4,335−136%−992% | 12,146+5196%613% | 229—122% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q1 FY2027to Sep 30, 2026 | Q4 FY2026to Jun 30, 2026 | Q3 FY2026to Mar 31, 2026 | Q2 FY2026to Dec 31, 2025 | Q1 FY2026to Sep 30, 2025 | Q4 FY2025to Jun 30, 2025 | Q3 FY2025to Mar 31, 2025 | Q2 FY2025to Dec 31, 2024 | Q1 FY2025to Sep 30, 2024 | Q4 FY2024to Jun 30, 2024 | Q3 FY2024to Mar 31, 2024 | Q2 FY2024to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 4,495+24.9%100% | 1,392+25.2%100% | 1,146*+35.8%100% | 1,061+17.6%100% | 897+21.0%100% | 1,112+11.4%100% | 844*+15.9%100% | 902−0.6%100% | 741−19.2%100% | 998—100% | 728*—100% | 908r824—100% | 917r764—100% | |
| Cost of revenue | 2,206+17.7%49.1% | 634+6.8%45.5% | 609*+19.9%53.2% | 525+35.6%49.5% | 437+13.7%48.7% | 594+12.9%53.4% | 508*—60.2% | 387−40.0%43.0% | 384−31.9%51.9% | 525—52.6% | — | 645—71.1% | 565—61.6% | |
| Gross profit | 2,290+61.4%50.9% | 758+46.3%54.5% | 537*+59.9%46.8% | 535+56.8%50.5% | 460+106%51.3% | 518+49.4%46.6% | 336*−58.9%39.8% | 341+91.3%37.8% | 223+12.0%30.1% | 347—34.7% | 816*—112% | 178—19.7% | 199—21.7% | |
| Selling, general and administrative | 10,365+7.4%231% | 2,580−4.7%185% | 2,990*+9.8%261% | 2,459+1.8%232% | 2,337+29.2%261% | 2,707—243% | 2,723*—323% | 2,415—268% | 1,809+6.1%244% | — | — | — | 1,705—186% | |
| General and administrative | — | 2,580−4.7%185% | — | — | — | 2,707r2,660+38.9%243% | 2,753r2,718*+3.1%326% | 2,408−0.8%267% | 1,809+6.1%244% | 1,949—195% | 2,671*—367% | 2,426—267% | 1,705—186% | |
| Operating expenses | 15,214+15.0%338% | 3,646−1.8%262% | 4,751*+24.2%415% | 3,648+18.6%344% | 3,168+20.9%353% | 3,713r3,711+16.1%334% | 3,826r3,821*+3.3%453% | 3,075r3,068−4.4%341% | 2,621+11.8%354% | 3,198—320% | 3,705*—509% | 3,216—354% | 2,344—256% | |
| Operating income | −12,234—−272% | −2,683—−193% | −3,969*—−346% | −2,947—−278% | −2,636—−294% | −3,001r−3,000—−270% | −3,106r−3,102*—−368% | −2,560r−2,553—−284% | −2,264—−306% | −2,725—−273% | −2,812*—−386% | −2,954—−325% | −1,991—−217% | |
| Interest and finance income | 123+115%2.7% | 21+148%1.5% | 47*+419%4.1% | 49+180%4.7% | 5.3−75.7%0.6% | 8.5−83.9%0.8% | 9.1*−87.2%1.1% | 18+66.2%2.0% | 22+525%3.0% | 53—5.3% | 71*—9.7% | 11—1.2% | 3.5—0.4% | |
| Interest expense and finance costs | 65+124%1.5% | 1.4−37.9%0.1% | 3.3*−37.9%0.3% | 4.2−46.4%0.4% | 56+316%6.3% | 2.3r3.9−89.7%0.2% | 5.3r10*−90.3%0.6% | 7.9r15−81.4%0.9% | 14−58.4%1.8% | 22—2.2% | 55*—7.5% | 43—4.7% | 32—3.5% | |
| Other non-operating income (expense) | 92+238%2.1% | 14+131%1.0% | 51*+1269%4.5% | 77+702%7.3% | −51−762%−5.7% | 6.2r4.6−79.7%0.6% | 3.7r−1.0*−77.1%0.4% | 9.7r2.6—1.1% | 7.7−48.7%1.0% | 30—3.1% | 16*—2.2% | −33—−3.6% | 15—1.6% | |
| Net income including minority interests | −12,142—−270% | −2,668—−192% | −3,917*—−342% | −2,870—−271% | −2,687—−300% | −2,995—−269% | −3,103*—−368% | −2,551—−283% | −2,257—−305% | −2,695—−270% | −2,795*—−384% | −2,987—−329% | −1,976—−215% | |
| Minority interests' share of net income | −36—−0.8% | −10—−0.7% | −9.8*—−0.9% | −6.9—−0.7% | −9.0—−1.0% | −12—−1.1% | −13*—−1.5% | −7.1—−0.8% | −7.3—−1.0% | −9.2—−0.9% | −11*—−1.5% | −9.1—−1.0% | −6.7—−0.7% | |
| Net income attributable to shareholders | −12,106—−269% | −2,658—−191% | −3,908*—−341% | −2,863—−270% | −2,678—−299% | −2,983—−268% | −3,090*—−366% | −2,544—−282% | −2,249—−304% | −2,686—−269% | −2,784*—−383% | −2,978—−328% | −1,970—−215% | |
| Earnings per share, basic | — | -0.86—— | — | -1.80—— | -2.82—— | -3.49r-0.35—— | — | -4.41r-0.44—— | -4.96r-0.50—— | -0.70—— | — | -1.43—— | -2.07—— | |
| Earnings per share, diluted | — | -0.86—— | — | -1.80—— | -2.82—— | -3.49r-0.35—— | — | -4.41r-0.44—— | -4.96r-0.50—— | -0.70—— | — | -1.43—— | -2.07—— | |
| Shares, weighted average (basic) | 3.1+262%— | 3.1+262%— | — | 1.6+176%— | 1.0+110%— | 0.9r8.5−77.6%— | — | 0.6r5.8−72.2%— | 0.5r4.5−52.2%— | 3.8—— | — | 2.1—— | 0.9—— | |
| Shares, weighted average (diluted) | 3.1+262%— | 3.1+262%— | — | 1.6+176%— | 1.0+110%— | 0.9r8.5−77.6%— | — | 0.6r5.8−72.2%— | 0.5r4.5−52.2%— | 3.8—— | — | 2.1—— | 0.9—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 5,930—43.5% | 5,930+257%43.5% | 3,992+291%33.4% | 6,862+144%46.2% | 740−67.0%4.2% | 1,660−58.4%16.5% | 1,020−83.8%12.4% | 2,807−70.1%29.3% | 2,242+100%25.8% | 3,989—34.0% | 6,304—45.8% | 9,398—55.2% | 1,119—12.7% | |
| Receivables | 1,000—7.3% | 1,000+39.3%7.3% | 848+42.7%7.1% | 878+71.9%5.9% | 457+71.6%2.6% | 718+24.1%7.2% | 595+38.4%7.2% | 511+18.4%5.3% | 266+1.2%3.1% | 579—4.9% | 430—3.1% | 432—2.5% | 263—3.0% | |
| Inventory | 478—3.5% | 478−23.9%3.5% | 419−34.1%3.5% | 597−12.6%4.0% | 590−15.8%3.3% | 628−15.0%6.3% | 635−18.3%7.7% | 683−22.1%7.1% | 701−25.6%8.1% | 739—6.3% | 778—5.6% | 878—5.2% | 942—10.7% | |
| Other current assets | 1,108—8.1% | 1,108+127%8.1% | 1,031+24.7%8.6% | 843+44.0%5.7% | 480+37.7%2.7% | 488+23.2%4.9% | 827+66.2%10.0% | 585+21.7%6.1% | 349+5.2%4.0% | 396—3.4% | 498—3.6% | 481—2.8% | 332—3.8% | |
| Current assets | 9,045—66.4% | 9,045+102%66.4% | 7,097+71.5%59.4% | 9,750+90.9%65.6% | 12,175+200%69.0% | 4,484−30.8%44.7% | 4,139−51.5%50.2% | 5,107−55.7%53.3% | 4,062+37.9%46.8% | 6,479—55.3% | 8,534—61.9% | 11,521—67.6% | 2,945—33.4% | |
| Property, plant and equipment | 278—2.0% | 278+2.3%2.0% | 294+17.1%2.5% | 312−42.9%2.1% | 322−40.1%1.8% | 272−53.6%2.7% | 251−55.6%3.0% | 546−2.3%5.7% | 537−9.1%6.2% | 586—5.0% | 566—4.1% | 560—3.3% | 591—6.7% | |
| Right-of-use (leased) assets | 1,702—12.5% | 1,702−5.9%12.5% | 1,751+2419%14.7% | 1,802+1321%12.1% | 1,887+933%10.7% | 1,809+594%18.0% | 70−77.3%0.8% | 127−65.3%1.3% | 183−57.8%2.1% | 261—2.2% | 307—2.2% | 366—2.1% | 433—4.9% | |
| Other intangible assets | 2,596—19.1% | 2,596−25.3%19.1% | 2,799−26.1%23.4% | 2,999−21.2%20.2% | 3,269−16.2%18.5% | 3,473−21.1%34.6% | 3,790−13.3%45.9% | 3,804−17.2%39.7% | 3,903−19.7%44.9% | 4,400—37.5% | 4,372—31.7% | 4,593—27.0% | 4,858—55.0% | |
| Total assets | 13,622—100% | 13,622+35.7%100% | 11,942+44.8%100% | 14,863+55.1%100% | 17,653+103%100% | 10,038−14.4%100% | 8,250−40.1%100% | 9,585−43.7%100% | 8,684−1.6%100% | 11,726—100% | 13,779—100% | 17,039—100% | 8,827—100% | |
| Accounts payable | 3,669—26.9% | 3,669−8.1%26.9% | 712−20.6%6.0% | 3,636+173%24.5% | 4,261+296%24.1% | 3,992+118%39.8% | 897r4,534−47.4%10.9% | 1,331−37.5%13.9% | 1,075−39.0%12.4% | 1,834—15.6% | 1,705—12.4% | 2,129—12.5% | 1,763—20.0% | |
| Current liabilities | 4,578—33.6% | 4,578−9.6%33.6% | 4,929−7.9%41.3% | 4,611+1.0%31.0% | 5,127+16.5%29.0% | 5,062−10.9%50.4% | 5,351−1.8%64.9% | 4,564−20.0%47.6% | 4,403−15.1%50.7% | 5,679—48.4% | 5,451—39.6% | 5,706—33.5% | 5,183—58.7% | |
| Lease liabilities (non-current) | 1,636—12.0% | 1,636+12.9%12.0% | 1,672—14.0% | 1,460+39308%9.8% | 1,529+10420%8.7% | 1,449+5056%14.4% | — | 3.7−97.6%0.0% | 15−93.6%0.2% | 28—0.2% | 81—0.6% | 154—0.9% | 229—2.6% | |
| Total liabilities | 6,269—46.0% | 6,269−5.2%46.0% | 6,651+22.4%55.7% | 6,111+31.7%41.1% | 6,763+50.9%38.3% | 6,611+14.5%65.9% | 5,436−2.9%65.9% | 4,641−23.2%48.4% | 4,481−21.0%51.6% | 5,777—49.3% | 5,596—40.6% | 6,041—35.5% | 5,673—64.3% | |
| Retained earnings | −77,622—−570% | −77,622—−570% | −74,964—−628% | −71,056—−478% | −68,194—−386% | −65,516—−653% | −62,533—−758% | −59,443—−620% | −56,899—−655% | −54,650—−466% | −51,964—−377% | −49,180—−289% | −46,202—−523% | |
| Shareholders' equity | 7,583—55.7% | 7,583+109%55.7% | 5,511+83.9%46.1% | 8,962+75.3%60.3% | 11,093+154%62.8% | 3,621−40.7%36.1% | 2,996−64.0%36.3% | 5,114−54.1%53.4% | 4,366+33.1%50.3% | 6,105—52.1% | 8,329—60.5% | 11,133—65.3% | 3,280—37.2% | |
| Minority interests | −230—−1.7% | −230—−1.7% | −220—−1.8% | −210—−1.4% | −203—−1.2% | −194—−1.9% | −182—−2.2% | −170—−1.8% | −163—−1.9% | −155—−1.3% | −146—−1.1% | −135—−0.8% | −126—−1.4% | |
| Total equity | 7,353—54.0% | 7,353+115%54.0% | 5,291+88.0%44.3% | 8,751+77.0%58.9% | 10,890+159%61.7% | 3,427−42.4%34.1% | 2,814−65.6%34.1% | 4,944−55.0%51.6% | 4,203+33.3%48.4% | 5,949—50.7% | 8,183—59.4% | 10,998—64.5% | 3,154—35.7% | |
| Total liabilities and equity | 13,622—100% | 13,622+35.7%100% | 11,942+44.8%100% | 14,863+55.1%100% | 17,653+103%100% | 10,038−14.4%100% | 8,250−40.1%100% | 9,585−43.7%100% | 8,684−1.6%100% | 11,726—100% | 13,779—100% | 17,039—100% | 8,827—100% | |
| Shares outstanding | 3.3—— | 3.3−63.5%— | 2.9+297%— | 2.0−70.5%— | 1.2−74.2%— | 9.1+108%— | 0.7r7.3−78.8%— | 6.8+133%— | 4.8+226%— | 4.4—— | 3.5—— | 2.9—— | 1.5—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1,154−0.0%25.7% | 294−3.1%21.1% | 288*+18.1%25.2% | 290−3.8%27.4% | 282−7.6%31.4% | 303r258+25.6%27.3% | 244*+7.1%28.9% | 302−5.3%33.5% | 305+5.1%41.2% | 242—24.2% | 228r236*—31.3% | 319—35.1% | 290—31.6% | |
| Share-based compensation | 270+649%6.0% | 98+720%7.1% | 97*+712%8.5% | 12—1.2% | 62*+413%6.9% | 12−94.1%1.1% | 12*−1.6%1.4% | 0−100%0.0% | 12*—1.6% | 202—20.2% | 12*—1.7% | 218—24.1% | — | |
| Cash from operating activities | −11,833—−263% | −2,753—−198% | −3,182*—−278% | −4,331*—−408% | −1,568*—−175% | −2,847—−256% | −2,210*—−262% | −2,755*—−305% | −2,325*—−314% | −2,387—−239% | −2,944*—−404% | −2,447*—−270% | −2,869*—−313% | |
| Capital expenditure | — | — | 0*—0.0% | — | −68*—−7.6% | −70—−6.3% | — | — | — | — | — | — | — | |
| Cash from investing activities | — | — | 0*—0.0% | 13*—1.2% | −28*—−3.1% | −70—−6.3% | −209*—−24.7% | −14*−664%−1.6% | — | — | −167*—−23.0% | 2.6*—0.3% | — | |
| Shares issued | — | — | — | — | — | — | — | 810—89.8% | 642—86.6% | 35—3.5% | — | — | — | |
| Cash from financing activities | 16,110+98.6%358% | 4,684+31.6%337% | 312*−48.2%27.2% | 10,439*+214%984% | 675*+6.8%75.2% | 3,558+8282%320% | 602*+11231%71.3% | 3,322*−69.2%368% | 632*—85.2% | 42—4.3% | 5.3*—0.7% | 10,769*—1186% | — | |
| Change in cash | 4,270—95.0% | 1,938+203%139% | −2,870*—−250% | 6,122*+984%577% | −920*—−103% | 640—57.6% | −1,787*—−212% | 565*−93.2%62.6% | −1,747*−287%−236% | −2,315—−232% | −3,093*—−425% | 8,279*—912% | 933*—102% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Intelligent Bio Solutions Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Sales of Goods - Cartidges$2 M59%+41%
- Sales of Goods - Readers$1 M21%+27%
- Other sales - accessories$1 M20%+43%
Countries and regions
- 🇬🇧 UK$4 M99%+45%
- Other Country$0 M0.9%-69%
- Americas$0 M0.2%-50%
- Asia Pacific$0 M0.3%-67%
Source: SEC annual report (XBRL data) · as of Jun 30, 2026
Where Intelligent Bio Solutions Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Intelligent Bio Solutions Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Mr. Harry Simeonidis | $661 K | $621 K | $522 K | $1 |
| 2025Mr. Harry Simeonidis | $562 K | $574 K | $424 K | $5 |
| 2024Mr. Harry Simeonidis | $447 K | $447 K | $337 K | $6 |
Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026
Events at Intelligent Bio Solutions Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 1 · Material agreement 2 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $5 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Dec 2025 | $10 M | Private placement after listing | $2 to $10 million | 2 | equity, options | SEC |
| Jul 2025 | $4 M | Private placement after listing | $2 to $10 million | 7 | options | SEC |
| Mar 2024 | $10 M | Private placement after listing | $10 to $50 million | 8 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Intelligent Bio Solutions Inc. compares in Healthcare
- Market cap$6 M · higher than 5% of 2,013
- Revenue$4 M · higher than 17% of 1,795
- Net margin-269.1% · higher than 8% of 1,485
- Revenue growth38.4% · higher than 80% of 1,003
- Price / sales1.3× · lower than 78% of 1,071
- Price / book1.0× · lower than 81% of 1,245
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Intelligent Bio Solutions Inc.🇺🇸 | $6 M | — | -269.1% | +38.4% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 22, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Employees:
- As of June 30, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Intelligent Bio Solutions Inc.? Verify and update this profile — free
Show Intelligent Bio Solutions Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.